FDA broadens authorization for Akili's video game for ADHD
The FDA has broadened the label for Akili’s prescription video game to treat pediatric ADHD as the company retools with a new over-the-counter focus.
EndeavorRx became the first video game to win FDA authorization as a mental health treatment in 2020. While the game was initially launched as an alternative to traditional ADHD treatment for kids 8 to 12 years old, regulators have now expanded the authorization to include teenagers 13 to 17 years old. Akili says the new label should “more than double” the number of children eligible for a prescription.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
